ARS Pharmaceuticals, Inc. Chief Legal Officer John L. Slebir filed a statement of changes in beneficial ownership on November 4, 2026, disclosing the acquisition of stock options on November 2, 2026.
An initial statement of beneficial ownership was filed on November 4, 2026, disclosing that Helen Jane Sheirbon became an officer of Avery Dennison Corp, listed on the New York Stock Exchange as NYSE:AVY, following a triggering event dated November 3, 2026.
Da-Wai Hu, Executive Vice President and General Counsel of Live Nation Entertainment, Inc., filed a Form 3 initial statement of beneficial ownership with the SEC on November 4, 2026, reflecting a triggering event date of November 2, 2026.
John L. Slebir, Chief Legal Officer of ARS Pharmaceuticals, Inc., filed a Form 3 initial statement of beneficial ownership with the SEC on November 4, 2026, disclosing no securities beneficially owned as of the event date of October 26, 2026.
Robert Wong, VP and Chief Accounting Officer of Retension Pharmaceuticals, Inc., reported the grant of 25,000 stock options on November 2, 2026, in a statement of changes in beneficial ownership filed with the SEC on November 4, 2026.
Director Robert Garechana filed a Form 4 with the SEC on November 4, 2026, disclosing the acquisition of 1,938 restricted stock units in InvenTrust Properties Corp. (NYSE:IVT).
InvenTrust Properties Corp. filed a Form 8-K on November 4, 2026, disclosing the appointment of Robert A. Garechana to its Board of Directors and Audit Committee, effective immediately.
Salvatore J. Ternullo, Chief Executive Officer and Director of SVRN, Inc., filed an amended initial statement of beneficial ownership on November 4, 2026, correcting how a restricted stock award was previously categorized and reflecting share counts adjusted for a 1-for-20 reverse stock split.
Robert Garechana submitted an initial statement of beneficial ownership as a newly appointed director of InvenTrust Properties Corp., filed on November 4, 2026, disclosing no securities beneficially owned.
Robert Wong, VP and Chief Accounting Officer of Retension Pharmaceuticals, Inc., filed an initial statement of beneficial ownership with the SEC on November 4, 2026, disclosing no securities held as of his event date of November 2, 2026.